» Articles » PMID: 11705883

Tumor Targeting and Imaging of Intraperitoneal Tumors by Use of Antisense Oligo-DNA Complexed with Dendrimers And/or Avidin in Mice

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2001 Nov 14
PMID 11705883
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

To establish an effective nonviral gene delivery and a corresponding imaging method for i.p.-disseminated tumors, various oligonucleotide-carrier complexes were synthesized, and their in vitro and in vivo properties were examined. The 20-mer multiamino-linked oligonucleotide (oligo), synthesized as antisense against the c-erbB-2 sequence, and the 3'-biotinylated form of the same oligonucleotide (oligo-Bt) were (111)In labeled through a diethylenetriaminepentaacetic acid chelate. (111)In-oligo was mixed with generation 4 polyamidoamine dendrimer (G4) or with biotinylated G4 (G4-Bt), which are positively charged to form electrostatic complexes. (111)In-oligo/G4-Bt and (111)In-oligo-Bt were conjugated to avidin ((111)In-oligo/G4-Av and (111)In-oligo-Av, respectively). (111)In-oligo/G4, (111)In-oligo/G4-Av, (111)In-oligo-Av, and carrier-free (111)In-oligo (2.96 kBq/22.4-45.9 ng of oligo) were examined for internalization in vitro in human ovarian cancer cells (SHIN3). Biodistribution of (111)In-oligo-carrier complexes or (111)In-oligo was examined in normal (n = 4-7) or i.p. SHIN3 tumor-bearing (n = 6-10) mice 2-24 h after i.p. injection (74 kBq/125-300 ng). Scintigraphy of i.p. tumor-bearing and normal mice was performed at various times postinjection of (111)In-oligo-carrier complex or (111)In-oligo (1.85 MBq/2.2 ng). (111)In-oligo-carrier complexes bound to the tumor cells were internalized at a rate of 34-56% at 24 h. In vivo, G4, G4-Av, and Av significantly enhanced tumor delivery of (111)In-oligo [9.1, 14.5, and 24.4% of injected dose per g of tissue (ID/g) at 24 h; P < 0.05, < 0.01, and < 0.0001, respectively] compared with delivery without carrier (0.8% ID/g). Scintigrams of (111)In-oligo delivered to the i.p.-disseminated tumors by the carriers were successfully obtained. In conclusion, G4, G4-Av, and Av can effectively deliver (111)In-oligo to i.p.-disseminated tumors. (111)In-oligo-carrier complexes also have potential as tracers for imaging and monitoring of gene delivery.

Citing Articles

Development of Novel Pt-Labeled Hoechst33258: Pt Is More Suitable than In for Targeting DNA.

Obata H, Tsuji A, Kumata K, Sudo H, Minegishi K, Nagatsu K J Med Chem. 2022; 65(7):5690-5700.

PMID: 35358392 PMC: 9014856. DOI: 10.1021/acs.jmedchem.1c02209.


In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([Pt]cisplatin) Emitting Auger Electrons.

Obata H, Tsuji A, Sudo H, Sugyo A, Minegishi K, Nagatsu K Int J Mol Sci. 2021; 22(9).

PMID: 33924843 PMC: 8124180. DOI: 10.3390/ijms22094622.


Synthesis of no-carrier-added [Pt]cisplatin from a cyclotron produced PtCl complex.

Obata H, Minegishi K, Nagatsu K, Ogawa M, Zhang M Sci Rep. 2021; 11(1):8140.

PMID: 33854142 PMC: 8046966. DOI: 10.1038/s41598-021-87576-2.


Alzheimer's Disease - Future Therapy Based on Dendrimers.

Aliev G, Ashraf G, Tarasov V, Chubarev V, Leszek J, Gasiorowski K Curr Neuropharmacol. 2018; 17(3):288-294.

PMID: 30227819 PMC: 6425077. DOI: 10.2174/1570159X16666180918164623.


Technetium-99m chelator-free radiolabeling of specific glutamine tumor imaging nanoprobe: in vitro and in vivo evaluations.

Ghoreishi S, Khalaj A, Sabzevari O, Badrzadeh L, Mohammadzadeh P, Mousavi Motlagh S Int J Nanomedicine. 2018; 13:4671-4683.

PMID: 30154653 PMC: 6103604. DOI: 10.2147/IJN.S157426.